Precision NanoSystems’ CEO and Co-Founder, James Taylor, is Chosen as One of Business in Vancouver’s 2013/14 Top 40 Under 40

Press Release

May 15, 2014

Vancouver, BC, Canada

Every year, Business in Vancouver recognizes outstanding managers, executives and entrepreneurs in the public, private and non-profit sectors. Winners are chosen by a panel of 5 judges from the Vancouver business community and are celebrated at a gala event in late January, 2014. Precision NanoSystems’ (PNI) CEO and co-founder James Taylor is proud to have been selected as part of this prestigious list. Dr. Taylor notes, “I am happy to be included among this outstanding group of individuals. This recognition is indicative of how quickly Precision NanoSystems has grown and I must credit the entire team for our success.”

Winners were featured in one-on-one interviews on CBC News Vancouver and CBC RadioOne where Dr. Taylor’s excellence in business judgment and leadership were highlighted as they pertained to PNI’s immersion into the rapidly growing nanomedicine industry.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.


IN THE NEWS

Press Release

Precision NanoSystems Inc. announces the launch of the NanoAssemblrTM SparkTM system to support nanoparticle researchers developing novel nucleic acid-based nanomedicines, including mRNA and CRISPR/Cas9 therapeutics....

Read More


Press Release

Precision NanoSystems, Inc. (PNI), a global nanomedicine company, has announced the completion of a $13.4 million private Series A financing. The investment was led by 5AM Ventures and Telegraph Hill Partners, with additional participants that incl...

Read More